Details for Patent: 10,653,710

✉ Email this page to a colleague

Which drugs does patent 10,653,710 protect, and when does it expire?

Patent 10,653,710 protects TIBSOVO and is included in one NDA.

This patent has thirty-three patent family members in twenty-eight countries.

Summary for Patent: 10,653,710

Patent landscape, scope, and claims:

Title:	Combination therapy for treating malignancies
Abstract:	Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethy- l)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-car- boxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.
Inventor(s):	Agresta; Samuel V. (Lexington, MA), Viswanadhan; Krishnan (East Hanover, NJ), DiMartino; Jorge (Belmont, CA), Chopra; Vivek Saroj Kumar (South San Francisco, CA), MacBeth; Kyle J. (San Francisco, CA), Knight; Robert Douglas (Berkeley Heights, NJ), Kenvin; Laurie (New Hope, PA), Xu; Qiang (Bernards, NJ)
Assignee:	Agios Pharmaceuticals, Inc. (Cambridge, MA) Celgene Corporation (Summit, NJ)
Application Number:	15/767,822
Patent Claim Types: see list of patent claims	Use; Composition;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 10,653,710

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes	10,653,710	⤷ Subscribe				A METHOD FOR TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 SELECTED FROM R132H, R132C, R132L, R132V, R132S AND R132GF BY ADMINISTERING IVOSIDENIB AND AZACITIDINE	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,653,710

PCT Information
PCT Filed	October 14, 2016	PCT Application Number:	PCT/US2016/057042
PCT Publication Date:	April 20, 2017	PCT Publication Number:	WO2017/066571

International Family Members for US Patent 10,653,710

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016338557	⤷ Subscribe
Brazil	112018007656	⤷ Subscribe
Brazil	122024000250	⤷ Subscribe
Canada	3002068	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.